

Immune response after rabies pre-exposure prophylaxis and a booster dose in Australian bat carers

Yihan Guo¹, Deborah J Mills², Colleen L Lau^{2,3}, Christine Mills², Luis Furuya-Kanamori³

¹ School of Medicine, Faculty of Medicine, The University of Queensland, St Lucia, Australia

² Dr Deb The Travel Doctor, Travel Medicine Alliance, Brisbane, Australia


³ School of Public Health, Faculty of Medicine, The University of Queensland, Herston, Australia



Source: Adobe Stock

Introduction

- Rabies is an invariably fatal, but vaccine-preventable viral zoonosis in humans.¹ Although Australia is currently rabies-free, bat lyssavirus, which is closely related to rabies, has been widely identified Australian bats.²
- Periodic vaccination against rabies is essential for individuals at continuing risk of rabies exposure.
- There is limited evidence on long-term immunogenicity after a three-dose intramuscular (3IM) pre-exposure prophylaxis (PrEP) and single IM booster dose.
- This study investigated post-PrEP and post-booster persistence of antibodies in Australian bat carers in order to generate evidence for optimal PrEP and testing/booster intervals.



Methods

- Data from 305 bat carers who received 3IM PrEP/booster doses and had post-PrEP/booster serology test results were included and analysed.
- The proportion of **antibody-negative (<0.5 EU/mL)** individuals after PrEP/booster dose were examined.

References:

- World Health Organization. Rabies vaccines: WHO position paper, April 2018–Recommendations. *Vaccine*, 2018. 36(37): p. 5500-5503.
- Merritt, T., et al., Australian bat lyssavirus. *Australian Journal of General Practice*, 2018. 47(3): p. 93-96.

Results




Figure 1. Antibody titre levels (EU/mL) stratified by time since 3IM PrEP in the sample of 305 Australian bat carers




Figure 2. Antibody titre levels (EU/mL) stratified by time since the first booster dose in the sample of 91 Australian bat carers

Conclusion

- For individuals at continuing risk of rabies exposure, a serology test should be performed **one year** after 3-dose intramuscular pre-exposure prophylaxis, followed by a booster if the antibody level is below the protective threshold.
- The interval between the first booster dose and subsequent serology tests should be **no longer than three years**.
- Age is an important predictor of rabies antibody positivity. Older individuals are more likely to turn antibody-negative quickly after vaccination.
- Future research should be undertaken to provide more insight into the appropriate timing of subsequent booster doses.

Acknowledgements

I would like to thank my research supervisors Dr Luis Furuya-Kanamori, Dr Deborah Mills and Professor Colleen Lau for their advice and guidance during the past 2 years.

Connect with me

yihan.guo1@uqconnect.edu.au